The cardioprotective effects of sEH inhibitors are gradually expanding therapeutically toward renal diseases, including hypertension, diabetic nephropathy, drug-induced nephrotoxicity, and renal fibrotic disease [73]. Here, EPHX2 is linked to diabetic kidney disease.